Therapeutic apheresis: History, clinical application, and lingering uncertainties

Transfusion

Volumn 50, Issue 7, 2010, Pages 1413-1426

  McLeod, Bruce C ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN;

APHERESIS; AUTOIMMUNE DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CRYOGLOBULINEMIA; EATON LAMBERT SYNDROME; ERYTHROCYTE EXCHANGE; ERYTHROCYTE TRANSFUSION; FAMILIAL HYPERCHOLESTEROLEMIA; FREEZE DRYING; GOODPASTURE SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE COMPLEX NEPHRITIS; KIDNEY GRAFT REJECTION; LEUKAPHERESIS; LEUKOCYTOSIS; LEUKOSTASIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL INSTRUMENTATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; PARAPROTEINEMIA; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCAL INFECTION; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PUVA; RASMUSSEN SYNDROME; REFSUM DISEASE; REVIEW; SICKLE CELL ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; WEGENER GRANULOMATOSIS;

ADAM PROTEINS; BLOOD COMPONENT REMOVAL; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 77954331947     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02505.x     Document Type: Review

References (117)

1. Surgenor DM. Blood: the red fluid of the human body is a rich mixture of cells and molecules. New methods of fractionation and preserving these many constituents increase their usefulness to medicine. Sci Am 1954 190 : 54 62.
2. Tullis JL. Principles involved in glycerolization and deglycerolization of red cells using the Cohn fractionator. In : Proceedings of a Conference on Plasma Proteins and Cellular Elements of the Blood, November 15, 1954.
3. Tullis JL, Tinch RJ, Baudanza P, Gibson JG 2nd., DiForte S, Conneely G, Murthy K. Plateletpheresis in a disposable system. Transfusion 1971 11 : 368 77.
4. Judson G, Jones A, Kellogg R, Buckner D, Eisel R, Perry S, Greenough W. Closed continuous-flow centrifuge. Nature 1968 217 : 816 8.
5. Corbin F, Cullis HM, Freiriech EJ, Ito Y, Kellog RM, Latham A, McLeod BC. Development of apheresis instrumentation. In : McLeod BC, Price TH, Weinstein R, editors. Apheresis: principles and practice. 2nd ed.
6. Ito Y, Suaudeau J, Bowman RL. New flow-through centrifuge without rotating seals applied to plasmapheresis. Science 1975 189 : 999 1000.
7. Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration, I: in vitro transport characteristics of a hollow fiber blood ultrafilter. J Lab Clin Med 1975 85 : 355 71.
8. Smith JW, Malchesky PS, Nosé Y. Membrane plasmapheresis and the developing technology of plasma therapy. Cleve Clin Q 1984 51 : 135 42.
9. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999 39 : 282 8.
10. McMinn JR Jr., Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. A study of 78 additional patients. Transfusion 2003 43 : 415 6.
11. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christensen I, Oster M, Henigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987 316 : 297 303.
12. Vamvakas EC, Pineda AA. Selective extraction of plasma constituents. In : McLeod BC, Price TH, Weinstein R, editors. Apheresis: principles and practice. 2nd ed.
13. Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther 1914 5 : 625 41.
14. Schwab PJ, Fahey JL. Treatment of Waldenström's macroglobulinemia by plasmapheresis. N Engl J Med 1960 263 : 574 9.
15. Vallejos CS, McCredie KB, Brittin GM, Freireich EJ. Biological effects of repeated leukapheresis of patients with chronic myelogenous leukemia. Blood 1973 42 : 925 33.
16. Greenberg B, Watson-Williams E. Successful control of life-threatening thrombocytosis with a blood processor. Transfusion 1975 15 : 620 2.
17. Watson WJ, Katz VL, Bowes WA. Plasmapheresis during pregnancy. Obstet Gynecol 1990 76 : 451 7.
18. Jones JV, Cumming RH, Bucknall RC, Asplin CM. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976 1 : 709 11.
19. Klein HG, Balow JE, Dau PC, Hamburger MI, Leitman SF, Pineda AA, Tindall RS. Clinical applications of therapeutic apheresis. J Clin Apheresis 1986 3 : 1 92.
20. Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC. An overview of current management. J Clin Apher 1993 189 94.
21. McLeod BC. Introduction to the third special issue: Clinical applications of therapeutic apheresis. J Clin Apher 2000 15 : 1 5.
22. Smith JW, Weinstein R, Lankford K. Therapeutic apheresis - a summary of current indication categories endorsed by AABB and ASFA. Transfusion 2003 43 : 820 2.
23. Szczepiorkowski ZW, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007 22 : 106 75.
24. McLeod BC. An approach to evidence based therapeutic apheresis. J Clin Apher 2002 17 : 124 32.
25. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ. Continuous plasmafiltration in sepsis syndrome. Crit Care Med 1999 27 : 2096 104.
26. Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemofiltration in critically ill patients. Therap Apher 2002 6 : 419 24.
27. Shariatmader S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte beads in thrombotic thrombocytopenic purpura. Am J Hematol 2005 79 : 83 8.
28. Jones JV, Cumming RH, Bacon PA, Evers J, Fraser ID, Bothamley J, Tribe CR, Davis P, Hughes GR. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979 48 : 555 76.
29. Kater L, Derksen RH, Houwert DA, Hené RJ, Struyvenberg A, Gmelig Meyling FH, Verroust P. Effect of plasmapheresis in active systemic lupus erythematosus. Neth J Med 1981 24 : 209 16.
30. Parry HF, Moran CJ, Snaith ML, Richards JD, Goldstone AH, Nineham LJ, Hay FC, Morrow WJ, Roitt IM. Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 1981 40 : 224 8.
31. Jones JV. Plasmapheresis in systemic lupus erythematosus. Clin Rheum Dis 1982 8 : 243 60.
32. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992 326 : 1373 9.
33. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998 13 : 163 6.
34. Schroeder JO, Schwab U, Zeuner R, Fastenrath S, Euler HH. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus: preliminary results of the LPSG trial. Arthritis Rheum 1997 40 : 325.
35. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985 35 : 1096 104.
36. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987 22 : 753 61.
37. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992 32 : 94 7.
38. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984 63 : 162 9.
39. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995 126 : 896 9.
40. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998 339 : 5 11.
41. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005 353 : 2769 78.
42. Pineda AA. Introduction. In : Pineda AA, editor. Selective plasma component removal.
43. Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc 2006 104 : 221 31.
44. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovancević B, Taylor DO, Jeevanandam V, Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998 339 : 1744 51.
45. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008 112 : 2667 74.
46. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008 135 : 400 9.
47. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med 2005 143 : 777 84.
48. Cserti C, Haspel R, Stowell C, Dzik W. Light chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007 47 : 511 4.
49. Cardella CJ, Sutton D, Uldall PR, de Veber GA. Intensive plasma exchange and renal transplant rejection. Lancet 1977 1 : 264.
50. Rifle G, Chalopin JM, Ture JM, Guigner F, Vialtel P, Dechelette E, Chenais E, Cordonsier D. Plasmapheresis in the treatment of renal allograft rejections. Transplant Proc 1979 11 : 20 6.
51. Adams MB, Kauffman HM Jr., Hussey CV, Gottschall JL, Hackbarth SA, Buchmann EV. Plasmapheresis in the treatment of refractory renal allograft rejection. Transplant Proc 1981 13 : 491 4.
52. Vangelista A, Frascà GM, Nanni Costa A, Stefoni S, Bonomini V. Value of plasma exchange in renal transplant rejection induced by specific HLA antibodies. Trans Am Soc Artif Intern Organs 1982 28 : 599 603.
53. Cardella CJ, Sutton DM, Falk JA, Katz A, Uldall PR, deVeber GA. Effect of intense plasma exchange on renal transplant rejection and serum cytotoxic antibody. Transplant Proc 1978 10 : 617 9.
54. Bankowski LH, Corteste J, Lutton JL, Saunders PH. Plasmapheresis - adjunctive treatment for steroid-resistant rejection in renal transplantation. J Urol 1984 131 : 14.
55. Soulillou JP, Guyot C, Guimbretiere J, Girard M, Ythier A, Bignon JD, Hourmant M, Guenel J. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 1983 35 : 158 62.
56. Allen NH, Ayer P, Geoghegan T, Harris K, Lee HA, Slapak M. Plasma exchange in acute renal allograft rejection: a controlled trial. Transplantation 1983 35 : 425 8.
57. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981 32 : 164 5.
58. Bonomini V, Vangelista A, Frascà GM, Di Felice A, Liviano D'Arcangelo G. Effects of plasmapheresis in renal transplant rejection: a controlled study. Trans Am Soc Artif Intern Organs 1985 31 : 698 703.
59. Blake P, Sutton D, Cardella C. Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res 1990 337 : 249 52.
60. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, Farrell ML, Williams WW, Delmonico FL, Cosimi AB, Colvin RB, Saidman SL. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001 71 : 652 8.
61. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000 70 : 887 95.
62. White NB, Greenstein SM, Cantafio AW, Schechner R, Glickligh D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, Tellis V. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004 78 : 772 4.
63. Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, Montgomery RA. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002 34 : 1614 6.
64. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr. Transplantation 2004 8 : 535 42.
65. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008 86 : 96 103.
66. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009 87 : 268 73.
67. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008 48 : 2453 60.
68. Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, Kraus ES. Subclinical acute anti-body mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007 7 : 576 85.
69. Pollinger HS, Stegall MD, Gloor JM, Moore SB, Degoey SR, Ploeger NA, Park WD. Kidney transplantation in patients with antibodies against donor HLA Class II. Am J Transplant 2007 7 : 857 63.
70. Lazda VA. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch. Transplantation 1994 57 : 964 9.
71. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007 357 : 1293 300.
72. Carter V, Shenton BK, Jaques B, Turner D, Talbot D, Gupta A, Chapman CE, Matthews CJ, Cavanagh G. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005 37 : 654 7.
73. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer H, Luft FC, Wallukat G. Angiotensin II type-1 receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005 352 : 558 69.
74. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Cur Opin Immunol 2008 20 : 607 13.
75. Compston A, Coles A. Multiple sclerosis. Lancet 2002 359 : 1221 31.
76. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994 44 : 16 20.
77. Goodin DS, Frohman EM, Garmany GP Jr., Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 58 : 169 78.
78. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008 255 : 1449 63.
79. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 2007 20 : 255 60.
80. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007 6 : 805 15.
81. Galetta SL, Bennett J. Neuromyelitis optica is a variant of multiple sclerosis. Arch Neurol 2007 64 : 901 3. (Pubitemid 46919850)
82. Dau PC, Petajan JH, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980 30 : 1023 8.
83. Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: preliminary study. Neurology 1980 30 : 1029 33.
84. Khatri BO, McQuillen MP, Hoffmann RG, Harrington GJ, Schmoll D. Plasma exchange in chronic progressive multiple sclerosis: a long term study. Neurology 1991 41 : 409 14.
85. Tindall RS, Walker JE, Ehle AL, Near L, Rollins J, Becker D. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 1982 32 : 739 43.
86. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983 308 : 173 80.
87. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985 35 : 312 9.
88. Weiner HL, Dau PC, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, Fosburg MT, Feldstein M, Orav EJ. Double-blind study of true versus sham plasma exchange in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989 39 : 1143 9.
89. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991 337 : 441 6.
90. Noseworthy JH, Vandervoort MK, Penman M, Ebers G, Shumak K, Seland TP, Roberts R, Yetisir E, Gent M, Taylor DW. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991 337 : 1540 1.
91. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999 46 : 878 86.
92. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966 45 : 139 59.
93. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977 50 : 413 7.
94. Okuno T, Kosova L. Plasmapheresis for thrombotic thrombocytopenic purpura. Transfusion 1979 19 : 342 4.
95. Taft EG. Thrombotic thrombocytopenic purpura and the dose of plasma exchange. Blood 1979 54 : 842 9.
96. Myers TJ, Wakem CJ, Ball ED, Tremont SJ. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Intern Med 1980 92 : 149 55.
97. McLeod B, Wu K, Knospe W. Plasmapheresis in thrombotic thrombocytopenic purpura. Arch Intern Med 1980 140 : 1059 60.
98. Breckenridge RL Jr., Solberg LA, Pineda AA, Petitt RM, Dharkar DD. Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience. J Clin Apher 1982 1 : 6 13.
99. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977 297 : 1386 9.
100. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006 354 : 1927 35.
101. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987 32 : 292 308.
102. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 112 : 11 8.
103. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome; clinical experience in 108 patients. N Engl J Med 1991 325 : 398 403.
104. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1997 325 : 393 7.
105. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 84. (Pubitemid 28536132)
106. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 : 1585 94.
107. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C, Garbrecht F, Gottschall JL. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995 16 : 271 5.
108. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004 103 : 4043 9.
109. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001 98 : 1765 72.
110. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 : 60 8.
111. Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004 44 : 146 50.
112. Zakarija A, Bandarenko N, Kwaan H, Pandey D, Cursio J, Tevar A, Buffie C, Weiss I, Ortel T, Winters J, Bennett CL. Risk factors for thrombotic thrombocytopenic purpura: results of the surveillance, epidemiology, and risk factors for TTP (SERF-TTP) group. J Clin Apher 2007 22 : 51 2 abstract).
113. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003 1 : 1882 7.
114. Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004 2 : 1601 9.
115. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002 100 : 4033 9.
116. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, López JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003 278 : 29633 9.
117. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005 3 : 1710 6.